SM
ITCI

Sabby Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Sabby Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100
Closed -$318K – 193
2020
Q4 		$318K Buy
+100
New +$2.63K 0.06% 73
2017
Q2 		– Sell
-158
Closed -$257K – 264
2017
Q1 		$257K Sell
158
-1,623
-91% -$23.5K 0.01% 207
2016
Q4 		$2.69M Buy
1,781
+1,248
+234% +$17.6K 0.16% 82
2016
Q3 		$812K Sell
533
-840
-61% -$34K 0.03% 199
2016
Q2 		$5.33M Buy
1,373
+353
+35% +$12.7K 0.28% 54
2016
Q1 		$2.84M Buy
1,020
+920
+920% +$30.7K 0.14% 72
2015
Q4 		$538K Sell
100
-1,278
-93% -$64.5K 0.03% 229
2015
Q3 		$5.52M Buy
1,378
+237
+21% +$7.73K 0.23% 75
2015
Q2 		$3.65M Buy
+1,141
New +$28.9K 0.13% 115

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Sabby Management's ITCI Position: Q1 2021 in Review

Sabby Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2021, closing a stake of 35,000 shares — an estimated $1.11M sold.

Sabby Management first reported a position in ITCI in Q1 2015 and held it in 6 quarters. The position peaked at $2.95M in Q3 2020. 170 funds tracked by Wall St. Rank hold ITCI as of Q1 2021.

  • Sabby Management reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2021 after selling out during the quarter.
  • Sabby Management sold 35,000 Intra-Cellular Therapies Inc. shares in Q1 2021, an estimated $1.11M.
  • Sabby Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 6 quarters.
  • Sabby Management's Intra-Cellular Therapies Inc. position peaked at $2.95M in Q3 2020.
  • 170 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2021.

Based on Sabby Management's 13F filing for Q1 2021, filed 17 May 2021.